News | December 17, 2024
Merck to acquire HUB Organoids to advance cell culture portfolio
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
Subscribe To Our Newsletter & Stay Updated
